NEWARK, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
Dear Fellow Shareholders,
As I mentioned in my last letter to shareholders, the pace of development at StemCells, Inc. has been accelerating quickly, so it is especially important to have regular updates to keep you informed of the remarkable progress we are making to advance stem cell science and cell-based medicine for intractable conditions of the central nervous system (the "CNS"). Over the past few months, in making presentations at several prestigious healthcare conferences, the Company's ongoing leadership position and recent clinical accomplishments have served as solid proof of the tangible value that we are creating. We believe this lead will extend quickly over the next year or two, as StemCells, begins reporting clinical data from its controlled Phase II studies in two indications, one in the eye and the other in the spinal cord."Much Ado About Nothing" or "Signs Of Things To Come"? We recently completed enrollment in our Phase I/II spinal cord injury trial, which represents the world's first test of human neural stem cell transplantation in chronic injury. The interim data from this trial includes evidence of return of function to the spinal cord below the site of the injury. Due to the severity and location of the injuries in these cases, the types and degrees of sensory function gain that we have reported were not expected by experts. The fact that four of the eight patients dosed, to-date, have experienced return of sensation is, in and of itself, very encouraging, but we believe the fact that the regained sensation extends to as many as six segments below the level of injury is suggestive of a fundamental regenerative process occurring in the spinal cord.